Several committees have been established to support the Office for Research & Innovation in overseeing the research and innovation activities of the institution. Below is information about the committees and their current membership.

Authorship Dispute Board

The Authorship Dispute Board will convene to hear matters of authorship dispute that cannot be resolved at the local level by the authors themselves or in consultation with the laboratory chief, chair or head of department(s), or dean, as appropriate. The Board will be composed of one chair and three additional faculty members jointly appointed by the Provost and the Dean of the School of Medicine and approved by the Executive Committee of the Academic Council, two ex officio members of the administration, the Vice President for Research & Innovation, and the Vice Dean for Basic Science, one graduate or professional student appointed by the Graduate and Professional Student Council, and one postdoctoral fellow appointed by the Duke University Postdoctoral Association. If appropriate, the Board may call upon the expertise of other members of the Duke University faculty. 

Term: Three Years

Conflict of Interest Committee (COI)

The Conflict of Interest Committee is charged with the protection of the integrity of Duke's research and educational missions, as well as the integrity of the organization and the individual.

  • Comprised of members from School of Medicine, School of Nursing and Campus
  • Governed by the policy related to research
  • Review/manage COI
  • Advise on Institutional Conflict of Interest (ICOI)
  • Other activities as appropriate

View COIC Charter

Executive Research Oversight Committee (EROC)

The overall goal of this body is to shape Duke’s research organization and activities to foster a strong culture of excellence in research and an empowered community that speaks up on concerns of scientific integrity. Specifically, the principal objectives are to:

  • Continually assess and quantify risk points within Duke’s research enterprise, and devise and implement procedures for risk mitigation.
  • Continually assess the infrastructure by which Duke handles research misconduct cases. This includes assessment of Duke’s structure in this area relative to national best practices, and a framework for continually measuring performance with quantifiable objective measures.
  • Weigh the merits and provide direction for the implementation of the recommendations of the President’s Advisory Panel on Scientific Integrity and Research Excellence to improve Duke’s research structures and functions.
  • Proactively monitor the external (national) environment, calibrate risks, and utilize findings to guide management of Duke’s research enterprise.
  • Work closely with the EROC’s Faculty Advisory Group to assess needs, propose solutions, and develop strategies and programs to influence faculty culture and accountability, foster community, provide professional support, improve communications, and achieve research excellence with an emphasis on scientific integrity.
  • Pamela Bernard - Vice President and General Counsel
  • Colin Duckett - Vice Dean for Basic Science, School of Medicine and Research Professor and Interim Chair of Pharmacology and Cancer Biology
  • Daniel Ennis - Executive Vice President
  • Jennifer Francis - Interim Provost and Robert L. Dickens Distinguished Professor of Business Administration
  • Christopher Freel - Associate Vice President for Research & Innovation
  • Scott Gibson - Executive Vice Dean for Administration, School of Medicine
  • Leigh Goller - Chief Audit, Risk, and Compliance Officer
  • Sönke  Johnsen - Professor of Biology
  • Jennifer Lodge - Vice President for Research & Innovation and Professor of Molecular Genetics and Microbiology
  • Jerry Lynch - Dean, Pratt School of Engineering and Professor of CEE
  • Mary Klotman - Dean, School of Medicine and R.J. Reynolds Professor of Medicine
  • Andrew Muir - Division Chief, Gastroenterology and Professor of Medicine
  • Rachel Satterfield - Vice President of Finance
  • Geeta Swamy - Associate Vice President for Research & Innovation, Vice Dean for Scientific Integrity, School of Medicine, and Associate Professor of Obstetrics and Gynecology
  • George Truskey - Associate Vice President for Research & Innovation and R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering
  • Eugene Washington - Chancellor for Health Affairs, Duke University, President and CEO of DUHS, and Professor of Obstetrics and Gynecology

EROC Faculty Subcommittee

Composed of research, academic, clinical, financial, and a select group of research-active faculty leaders, the overall goal of EROC is to shape Duke’s research organization and activities to foster a strong culture of excellence in research and an empowered community that speaks up on concerns of scientific integrity.

 To expand faculty involvement in addressing our research challenges, an advisory committee of faculty was constituted to assess needs, propose solutions, foster community, improve communications, promote excellence, and develop strategies and programs to influence faculty culture and accountability. The EROC Faculty Subcommittee is designed to provide a rich and diverse set of faculty perspectives on key issues and initiatives impacting Duke’s research enterprise. Input from the committee helps to guide the final policy and strategy directions decided by EROC.


  • Felipe De Brigard
  • Vic Szabo
  • Steffen Bass
  • Steve Craig
  • Katherine Franz
  • Sönke Johnsen
  • Greg Wray
  • Lisa Keister
  • Eddie Malesky
  • Charles Piot
  • Manju Puri
  • Jim Zhang
  • Ken Brown
  • Doriane Coleman
  • Sophia Smith
  • Maria Ciofani
  • Warren Kibbe
  • Stacy Horner
  • Shelley Hwang
  • Kimberly Johnson
  • Andrew Muir
  • Jonathan Posner
  • Kanecia Zimmerman

Office for Research and Innovation representatives:

  • John Dolbow
  • Christopher Freel
  • Jennifer Lodge
  • Mary Frances Luce
  • Geeta Swamy
  • George Truskey

Office for Translation and Commercialization (OTC) Board

The OTC Board consists of seven members. Five Board members shall be selected from the faculty and two from the administration. Three of the faculty members shall be selected by the Chancellor of Health Affairs (Chancellor), in consultation with the Dean of the SOM; the Provost shall select two faculty from Campus Schools in consultation with the Deans of those Schools. One of the Campus representatives shall be a faculty member in the Pratt School of Engineering. The Chancellor shall select the SOM administrative representative, and the Provost will select the Campus administrative representative. The Board will be co-Chaired by the Campus and SOM administrative representatives. The director of OTC shall be a non-voting ex-officio member of the Board and the Board shall designate an ex-officio Secretary of the Board. A designated member of the Counsel’s Office shall also be a non-voting ex-officio member of the Board. At the discretion of the Chancellor and Provost, a faculty member from the School of Law, with expertise in licensing and patent policy, may be added as an additional Board member. The director of OTC shall report jointly to the Provost and Chancellor, or their designees, who would be the administrative members of the Board. The Board shall:

  1. Receive and review the annual report of the Director of the Office of Translation & Commercialization and consult with the Director of the Office of Translation & Commercialization when requested.
  2. Report to the Provost and Chancellor or designees on the implementation of this policy, and recommend such new or different policies or guidelines as may be more suitable for the achievement of its objectives.
  3. Sit as a tribunal for the resolution of specific disputes involving the ownership of and equities involved in inventions, on appeal from decisions of the Director of the Office of Translation & Commercialization.
  4. Receive requests for interpretations of this policy and, after deliberation, recommend to the President such interpretations as it considers appropriate.
  5. Receive, review and recommend to the Chancellor and Provost the OTC budget as annually submitted by the Director of OTC.
  • Arti Rai, Elvin R. Latty Professor of Law
  • Cynthia Toth, MD, Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology
  • Donald McDonell , PhD, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology & Cancer Biology
  • Jeff Glass, PhD, Professor of Electrical and Computer Engineering
  • Jennifer West, PhD, Fitzpatrick Family University Distinguished Professor of Engineering
  • Jennifer Lodge, PhD, Vice President for Research and Innovation
  • Scott Gibson, MBA, Executive Vice Dean Admin, Finance and Resource Planning
  • Svati Shah, MD, Professor of Medicine

Research Administration Continuous Improvement (RACI) Committee

The Research Administration Continuous Improvement (RACI) Committee is convening space for all levels of research leadership to advise, prioritize, and implement strategic initiatives across the multifaceted enterprise to support the efficient and effective administration of research activities. It is charged with establishing priorities, responding to emerging areas of risk, and resolving complex issues in research administration that require coordination across departments and stakeholders.

RACI represents the necessary partnership between researchers, leadership and staff to effectively prepare individuals, units and the university to manage the evolving expectations and requirements of funders, publishers and regulatory bodies. RACI seeks to develop efficient technical, personnel, business and financial support structures that assist researchers and researcher administrators in effectively and compliantly conducting research. 


Coming soon

Research Policy Advisory Committee (RPAC)

The Research Policy Advisory Committee (RPAC) is advisory to the Vice President of Research & Innovation. It’s charged with reviewing and improving research policies and procedures, identifying policy and procedural gaps and challenges, and conducting an ongoing assessment of administrative burden with the goal of enhancing efficiencies and optimizing the conduct and administration of research at Duke University. To do so, the Committee is comprised of business and administrative leaders from the research enterprise at Duke University, as appointed by the Vice President of Research & Innovation in consultation with the Associate Vice Presidents for Research and the Research Policy Manager. Furthermore, the RPAC solicits faculty input and feedback through coordination and connections to the Faculty Subcommittee of the Executive Research Oversight Committee (EROC), and other guiding bodies in the University community as needed. The RPAC is the primary steward for completing the Research Policy Handbook.

Office of the ProvostChief of Staff, ProvostHallie Knuffman*
Office for Research & InnovationAssociate Vice Presidents for ResearchGeeta Swamy, MD Chris Freel, PhD, MBA
Duke Office of Scientific IntegrityAssistant Dean, Research FacilitationLindsey Spangler
School of Medicine Office of the DeanAssociate Dean, School of Medicine Research AdministrationLaurianne Torres
Office of CounselAssociate General CounselJudy Faubert
Financial CompliancePost Award Financial ManagementGail Bullock
Office of CounselAssociate General CounselScott Elengold, J.D.
Duke Office of Research InitiativesAssociate Director, Research OperationsJamie Wylie*
Office for Research & InnovationResearch Policy ManagerAlyssa Dack

*These individuals are included in order to provide strategic coordination and cohesion with key University initiatives, the Faculty Handbook and myRESEARCHpath.

**When determined necessary, the Policy Manager will invite other Institutional actors and leaders to provide input and expertise on areas such as International Research Administration, Conflict of Interest or Internal Review Board processes.